TORONTO, Dec. 18, 2013 /CNW/ -
|Subject:|| Recall of METHOTREXATE SODIUM INJECTION 25 mg/mL (2mL)
DIN 02099705 - Distributed by Teva Canada Limited (formerly Novopharm Limited)
Lots 12J30KK, 12J30KH, 12J30KB due to possible cracks in glass container
Teva Canada Limited, in consultation with Health Canada, is initiating a voluntary recall of 3 lots (listed above) of METHOTREXATE SODIUM INJECTION 25mg/mL (2mL) due to the possibility of cracks in the glass containers. This medication may be used in the treatment of cancer, psoriasis and arthritis related conditions.
Although this Product is used in hospitals and in cancer clinics, Health Canada has advised that there may be instances where it could be used by doctors in their office or by a patient in their own home.
This recall does not affect any other lots of METHOTREXATE SODIUM INJECTION supplied by Teva Canada.
This Public Communication is not intended as medical advice. In order to understand the implications of this information to your health and before you modify the way you use this health product, it is important that you consult your doctor or health care professional.
Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of unexpected side effects in patients receiving METHOTREXATE SODIUM INJECTION 25mg/mL (2mL) should be reported to Teva Canada or Health Canada.
| Medical Affairs Department
Teva Canada Limited
30 Novopharm Court
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, contact Health Canada at:
Lead Directorate: Health Products and Food Branch Inspectorate (HPFBI)
E-mail: [email protected]
"Original signed by"
Vice President, Quality and Compliance
Teva Canada Limited
SOURCE: Teva Canada Limited
For further information:
Vice-President, Corporate Communications - Americas